|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,526 GBX | -4.60% |
|
-5.69% | +5.23% |
| 05:57am | Sembcorp Inks Power Deals with GSK for Singapore Manufacturing Sites; Shares Down 3% | MT |
| Jun. 27 | Health Care Stocks Fall With Broad Market -- Health Care Roundup | DJ |
Feb 1 (Reuters) - GSK plc:
* BENLYSTA GRANTED ORPHAN DRUG DESIGNATION BY US FDA
* BENLYSTA GRANTED ORPHAN DRUG DESIGNATION BY US FDA FOR POTENTIAL TREATMENT OF SYSTEMIC SCLEROSIS
* GSK PLANS TO INITIATE A PHASE II/III TRIAL OF BELIMUMAB FOR SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE IN FIRST HALF OF 2023 Source text for Eikon: Further company coverage:
| 1st Jan change | Capi. | |
|---|---|---|
| +5.23% | 78.69B | |
| +55.95% | 819B | |
| +43.62% | 638B | |
| -6.98% | 351B | |
| +19.08% | 329B | |
| +9.05% | 298B | |
| +16.30% | 242B | |
| +2.41% | 225B | |
| +12.47% | 217B | |
| +8.91% | 168B |
GSK PLC 
